Immunoadjuvant Nanoparticles as Trojan Horses for Enhanced Photo-Immunotherapy in the Treatment of Triple-Negative Breast Cancer

被引:9
|
作者
Wu, Jinxian [1 ,2 ]
Wang, Shanyong [1 ,2 ]
Liu, Shanshan [1 ,2 ]
Liu, Fang [1 ,2 ]
Zhou, Feifan [1 ,2 ]
机构
[1] Hainan Univ, Sch Biomed Engn, Key Lab Biomed Engn Hainan Prov, Haikou, Peoples R China
[2] Hainan Univ, One Hlth Inst, Haikou, Peoples R China
基金
中国国家自然科学基金;
关键词
triple-negative breast cancer; nanoparticles; phototherapy; immunotherapy; metastasis; immune response;
D O I
10.3389/fphar.2022.883428
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Treatment of triple-negative breast cancer (TNBC) faces great challenges due to high invasiveness and poor prognosis. Therefore, effective treatment methods are urgently needed to control primary tumors and suppress distant tumors. Herein, we employed glycated chitosan (GC), a polysaccharide macromolecular immunoadjuvant, to construct a self-assembly GC@ICG nanoparticle which is accessible to tumor cells for synergistic cancer treatment based on the combination of phototherapy and immunotherapy. In this strategy, the self-associated synthesis of spherical GC@ICG significantly improved the stability of ICG and endowed GC with Trojan Horses in tumor cells to enhance tumor immunogenicity. A bilateral 4T1 tumor-bearing mouse model was established to evaluate the therapeutic outcomes and specific host antitumor immune response. Finally, GC@ICG-based phototherapy can directly eliminate primary tumors and resist the progression of untreated distant tumors. In addition, compared to the treatment of L + GC + ICG, GC@ICG-based phototherapy was evidenced to suppress lung metastasis and enhance infiltration of CD8(+) T cells in untreated distant tumors. Therefore, this design shows promise in addressing the challenges of the treatment of TNBC.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Combination of adenosine blockade and ferroptosis for photo-immunotherapy of triple negative breast cancer with aptamer-modified copper sulfide
    Zhang, Xingyu
    Shi, Chengyu
    Liu, Qiao
    Zhong, Yuting
    Zhu, Lipeng
    Zhao, Yuetao
    JOURNAL OF MATERIALS CHEMISTRY B, 2025, 13 (07) : 2504 - 2519
  • [32] Immunotherapy Treatment for Triple Negative Breast Cancer
    Berger, Elizabeth R.
    Park, Tristen
    Saridakis, Angeleke
    Golshan, Mehra
    Greenup, Rachel A.
    Ahuja, Nita
    PHARMACEUTICALS, 2021, 14 (08)
  • [33] Postneoadjuvant treatment for triple-negative breast cancer
    Trapani, Dario
    Ferraro, Emanuela
    Giugliano, Federica
    Bielo, Luca Boscolo
    Curigliano, Giuseppe
    Burstein, Harold J.
    CURRENT OPINION IN ONCOLOGY, 2022, 34 (06) : 623 - 634
  • [34] Treatment Horizons for Triple-negative Breast Cancer
    Yeo, W.
    HONG KONG JOURNAL OF RADIOLOGY, 2015, 18 (02): : 111 - 118
  • [35] Triple-negative breast cancer: is there a treatment on the horizon?
    Yao, Hui
    He, Guangchun
    Yan, Shichao
    Chen, Chao
    Song, Liujiang
    Rosol, Thomas J.
    Deng, Xiyun
    ONCOTARGET, 2017, 8 (01) : 1913 - 1924
  • [36] Atezolizumab for the treatment of triple-negative breast cancer
    Heimes, Anne-Sophie
    Schmidt, Marcus
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (01) : 1 - 5
  • [37] Targeted Treatment of Triple-Negative Breast Cancer
    Young, Joanna A.
    Tan, Antoinette R.
    CANCER JOURNAL, 2021, 27 (01): : 50 - 58
  • [38] Nanomedicine for the treatment of triple-negative breast cancer
    Kutty, Rajaletchumy Veloo
    Leong, David Tai Wei
    Feng, Si-Shen
    NANOMEDICINE, 2014, 9 (05) : 561 - 564
  • [39] Local Treatment of Triple-Negative Breast Cancer
    Machiels, Melanie
    Kaidar-Person, Orit
    Rubio, Isabel T.
    Poortmans, Philip
    CANCER JOURNAL, 2021, 27 (01): : 32 - 40
  • [40] The treatment landscape of triple-negative breast cancer
    Hu, Yi
    Wang, Chen
    Liang, Huishi
    Li, Jie
    Yang, Qiong
    MEDICAL ONCOLOGY, 2024, 41 (10)